Biotech News

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Ensysce Biosciences (ENSC)Ensysce Biosciences2026-06-25 13:46 ESTCompany update

ENSC (ENSC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ensc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Reports First Quarter 2026 Financial Results

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Expands Global Opioid Patent Portfolio

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

ENSCEnsysce Biosciences2026-06-25 13:46 EST

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

View all latest news

Ensysce Biosciences

Ensysce Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ENSCEnsysce Biosciences2026-06-26 07:11 EST

Ensysce Biosciences Reports First Quarter 2026 Financial Results

ENSCEnsysce Biosciences2026-06-26 07:11 EST

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

ENSCEnsysce Biosciences2026-06-26 07:11 EST

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

ENSCEnsysce Biosciences2026-06-26 07:11 EST

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

ENSCEnsysce Biosciences2026-06-26 07:11 EST

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States